Cagrilintide vs Retatrutide: Differences

The core difference is which receptor each molecule activates: cagrilintide is an amylin analogue that works on amylin/calcitonin receptors, while retatrutide is a triple agonist that activates GLP-1, GIP and glucagon receptors at the same time. They are not the same class of peptide, and the trials behind them were not built around the same design, even though both show up in the research literature on body weight and metabolism.

Cagrilintide vs retatrutide, side by side

What each molecule actually is

Amylin is a hormone the pancreas releases alongside insulin after a meal, and it plays a role in satiety signaling. Cagrilintide is a synthetic amylin analogue with an extended half-life, designed to sustain that effect longer than natural amylin does. It has been studied both on its own and in combination with semaglutide, in the molecule known as CagriSema.

Retatrutide belongs to a different class entirely: triple-action incretin agonists. In a single peptide chain, it combines activity on the GLP-1 receptor, the GIP receptor, and the glucagon receptor. That is the same "multiple receptors on one chain" logic already used by tirzepatide (GLP-1/GIP), extended with glucagon as a third target.

Why these two get compared so often

Both molecules compete in the same area of research — body weight regulation through hormones that govern appetite and metabolism — and both appeared in published studies in recent years with results that drew attention from the research community. But the mechanism does not overlap directly: amylin acts primarily on satiety centers in the brainstem, while incretin agonists act on receptors distributed across the pancreas, adipose tissue, liver and central nervous system. Being studied toward the same endpoint does not make them interchangeable at the receptor level.

Anyone trying to sort out the difference usually ends up comparing both against tirzepatide as well, which shares two of retatrutide's three receptors (GLP-1 and GIP) but does not include glucagon activity and has nothing in common with the amylin pathway.

CagriSema: where the two research paths actually cross

The one real point of contact between these two lines of research is CagriSema, the combination of cagrilintide and semaglutide evaluated in the REDEFINE program. Garvey et al., NEJM 2025 reported REDEFINE 1 in adults with overweight or obesity, and Davies et al., NEJM 2025 reported REDEFINE 2 in the same population with type 2 diabetes. In neither trial was cagrilintide combined with retatrutide — these are two separate clinical development programs, run by different sponsors, that do not converge into a single product.

Retatrutide, in every trial published so far, has been evaluated alone — not combined with cagrilintide or with any other amylin agonist — in the phase 2 obesity trial from Jastreboff et al., NEJM 2023, the phase 3 trial reported in Jastreboff et al., NEJM 2026, and the type 2 diabetes trial in Rosenstock et al., Lancet 2023. The ongoing trial registry can be checked directly at ClinicalTrials.gov.

Molecule vs product: what's already approved, and what isn't

It's worth separating two different questions here, because the US market already has approved products in this space. Semaglutide is the active ingredient in Ozempic and Wegovy, and tirzepatide is the active ingredient in Mounjaro and Zepbound — both approved by the FDA, with Zepbound's 2023 approval for chronic weight management confirmed in the FDA's own press announcement. Neither cagrilintide nor retatrutide has reached that point. Both are still in active clinical trials, and neither has an FDA-approved product built on it, whether alone or as CagriSema.

That distinction matters for anyone reading headlines about "the next weight loss drug": retatrutide and cagrilintide are investigational molecules, not brand-name medications on a pharmacy shelf. Material described in the research literature on these two compounds refers to studies in clinical trial populations, not to a product cleared for routine prescribing.

Regulatory status: neither one is approved

Neither cagrilintide nor retatrutide is approved by the FDA in the United States. Both are in phase 3 clinical development according to the public trial registries cited above, which means they are in the final stage of study before any eventual regulatory submission — not that they already carry marketing authorization anywhere. Any information about them reflects research results published in peer-reviewed journals, not a product cleared for routine clinical use.

That matters for anyone researching these molecules: the literature on both is growing quickly because they are in active trial phases, so what's published today can be updated or expanded by future papers.

Catalog and documentation

For researchers working with these molecules, PeptoClinic carries both retatrutide and cagrilintide in its catalog, and the retatrutide page for the Argentine market is one example of how each batch's documentation is published alongside its lab report. Every batch that ships, wherever it ships, goes through the same step: it's checked by an outside laboratory before it leaves, and the detail on how to read a certificate of analysis is on the quality page.